Nutlin-3, a small molecule inhibitor, activates p53 by disrupting p53-HDM2 association. In this study, we found that Nutlin-3 suppressed cell growth and induced apoptosis in the absence of wild-type p53, suggesting a p53-independent mechanism for Nutlin-3-induced cell death. Like p53, its homolog p73 transactivates proapoptotic genes and induces cell death. Since HDM2, a key negative regulator of p53, also binds to and inhibits p73, we asked whether p73 could mediate Nutlin-3-induced apoptosis. We demonstrate that Nutlin-3 inhibits endogenous binding between the proapoptotic p73 isoform TAp73a and HDM2 in p53-null cells. Dissociation of p73 and HDM2 leads to increased p73 transcriptional activity with upregulation of p73 target genes noxa, puma and p21, as well as enhanced apoptosis. p73 knockdown by siRNA results in rescue of Nutlin-3-treated cells, indicating that Nutlin-3-induced apoptosis is, at least in part, p73 dependent. In addition, Nutlin-3 treatment increases TAp73a protein levels with prolongation of p73 half-life. These results provide the first evidence that Nutlin-3 disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73 and thus, provides a rationale for the use of Nutlin-3 in the large number of human tumors in which p53 is inactivated.
Introduction p73, a member of the p53 family, is rarely mutated in cancers and encodes multiple functionally distinct isoforms due to alternative promoter utilization and mRNA splicing. The TAp73 full-length isoform contains a transactivation (TA) domain and can transactivate p53-responsive genes, thereby inducing apoptosis and cell cycle arrest. In contrast, the DNp73 isoforms lack the TA domain and act as dominant-negative inhibitors of the full-length p53 and p73 proteins (Irwin, 2004) . The HDM2 protein binds to and targets p53 for ubiquitin-mediated degradation by the proteosome (Iwakuma and Lozano, 2003) . The p53 binding site at the HDM2 N-terminus contains a well-defined hydrophobic pocket into which three p53 amino acid residues are inserted (Kussie et al., 1996) . Disruption of the p53-HDM2 complex through the use of small molecule inhibitors is therefore an attractive targeting strategy for anticancer treatments. Nutlin, a class of small molecule antagonist of HDM2, binds to the p53-binding pocket of HDM2, preventing p53 from binding to HDM2 and thus, resulting in stabilization and activation of p53 (Vassilev et al., 2004; Tovar et al., 2006) . Nutlin has recently been shown to be effective against a variety of cancer cells with wild-type (wt) p53 including neuroblastoma (Van Maerken et al., 2006) , retinoblastoma (Laurie et al., 2006) , osteosarcoma (Vassilev et al., 2004) and leukemia (Coll-Mulet et al., 2006) . p53 is tightly regulated by HDM2 via an autoregulatory feedback loop. HDM2 has also been shown to functionally interact with other proteins including p14ARF, Rb, E2F-1 (Iwakuma and Lozano, 2003) and p21 (Zhang et al., 2004) . Furthermore, when overexpressed, HDM2 also binds to other p53 family members p73 (Balint et al., 1999) and p63 (Kadakia et al., 2001) . Like p53, p73 binds to the N-terminal TA domain of HDM2 resulting in suppression of p73 transcriptional activity (Balint et al., 1999; Zeng et al., 1999) . HDM2 mutants lacking amino acid residues 58-89 do not interact with either p53 or p73, suggesting that both p53 and p73 bind to a similar region at the N-terminus of HDM2 (Balint et al., 1999) . In addition, HDM2 also binds to p53 through the central domain of HDM2 (Wallace et al., 2006) . While a second HDM2-binding site has been identified in the p53 core domain (Shimizu et al., 2002) , it is not known whether HDM2 also interacts with p73 outside the N terminus. Since the N-terminal HDM2-binding region of p53 is highly conserved in TAp73 and both p53-and p73-binding sites are within the hydrophobic pocket of HDM2, we hypothesized that Nutlin would inhibit the physical interaction between TAp73 and HDM2, thereby suppressing the inhibitory effects of HDM2 on TAp73, resulting in upregulation of TAp73 transcriptional activity and induction of apoptosis in cells lacking functional p53. In this study, for the first time we demonstrate an endogenous p73-HDM2 complex and report that disruption of this complex following Nutlin-3 treatment enhances p73 transcriptional activity and apoptosis, thus extending the potential therapeutic benefits of Nutlin to tumors with inactivated or mutant p53.
Results
Nutlin-3 inhibits cell growth in p53-mutant or p53-deficient cells We first investigated whether Nutlin-3 could inhibit cell proliferation in the absence of wt p53. Nutlin-3 treatment resulted in dose-dependent growth inhibition in p53-mutant SK-N-BE2 neuroblastoma (IC 50 : 29.577.8 mM), p53-null colon carcinoma (HCT116(p53À/À) (IC 50 : 33.071.9 mM) and p53-null osteosarcoma cells (SAOS2) (IC 50 : 33.671.3 mM) (Figure 1 ). In comparison, the IC 50 of wt p53 cells was lower at 2.370.9 mM (HCT116 (p53 þ / þ )) and 4.770.3 mM (IMR-5). This sensitivity of p53-null and p53-mutant cells suggests that Nutlin-3 can induce apoptosis via p53-independent pathways.
Disruption of endogenous p73-HDM2 binding by Nutlin-3 p73 binds to the HDM2 N-terminal hydrophobic pocket (Zeng et al., 1999) , which is the region targeted by Nutlin-3. We therefore asked whether Nutlin-3 could disrupt p73 binding to HDM2. We first demonstrated that endogenous p73a coimmunoprecipitated with HDM2 in both p53-null HCT116(p53À/À) and SAOS2 cells (Figures 2a and b) . Since HDM2 is predicted to bind to the N-terminal TA domain of p73, only the fulllength TAp73, but not DNp73 isoforms that lack the TA domain, would be expected to bind HDM2. Utilizing a TA-specific antibody raised against the N-terminus of p73, endogenous HDM2 was shown to interact with the TA isoform of p73a (Figure 2a ). We next determined the Nutlin-3 dose required to inhibit p73-HDM2 binding. Nutlin-3 treatment of HCT116(p53À/À) cells resulted in dose-dependent inhibition of TAp73a and HDM2 binding (Figure 2c ), which occurred as early as 1 and up to 24 h following treatment (Figure 2d ). To investigate whether p73 binds HDM2 directly, we immunoprecipitated in vitro translated p73 and HDM2 proteins. p73 and HDM2 recombinant proteins formed a complex, which was disrupted by Nutlin-3 treatment (Figure 2e ).
Nutlin-3 increases p73 transcriptional activities Cotransfection of HDM2 inhibits p73 transcriptional activity, at least in part, by binding to the TA domain of TAp73 (Balint et al., 1999; Zeng et al., 1999) . Thus, the dissociation of p73 from HDM2 by Nutlin-3 would be expected to upregulate p73-dependent transcription. We therefore examined the effect of Nutlin-3 on the expression level of p73 target genes. Noxa, puma and p21 waf1/cip1 mRNA levels increased by 2.5-, 2.3-and 3.2-fold, respectively, following Nutlin-3 treatment (Figures 3a and b and Supplementary Figure S1 ). Furthermore, in HCT116(p53À/À) and p53-mutant SK-N-BE2 cells Nutlin-3 treatment resulted in upregulation of noxa protein and induction of apoptosis, as measured by poly-(ADP-ribose)polymerase (PARP) cleavage (Figures 3c and d) .
Nutlin-mediated effects are p73 dependent To determine whether Nutlin-induced apoptosis is specifically dependent on p73 induction, we inhibited p73 expression and activity by siRNA and by overexpression of p73 dominant-negative (p73DD) protein. p73 knockdown, using siRNAs specific to p73 and with no significant homology to p63 (Supplementary Figure  S2a) , resulted in 90% inhibition of p73 expression, as measured by densitometry. This led to rescue of Nutlin-3-treated cells as shown by diminished expression of noxa, cleaved-PARP and p21
waf1.1/cip1 ( Figure 4 and Supplementary Figure S2b) . Furthermore, cells with stable overexpression of p73DD, but not mutant p73DD (L371P) (Irwin et al., 2000) , expressed lower levels of noxa following Nutlin-3 treatment (Supplementary Figure S3 ). As there is significant sequence homology among the p53 family proteins and p73DD can inhibit both p63 and p73 (Irwin et al., 2000) , we . Nevertheless, together with our p73-specific siRNA results, our data suggest that the p53-independent Nutlin-mediated effects are due to upregulation of TAp73 and its transcriptional activity.
Nutlin-3 increases p73 protein levels and stabilizes p73 Nutlin abrogation of p53-HDM2 association affects both p53 activity and stability, as well as increasing HDM2 levels via an autoregulatory feedback loop in which p53 transactivates HDM2 (Vassilev et al., 2004; Van Maerken et al., 2006) . Interestingly, several studies have shown that in contrast to p53, p73 is not degraded by HDM2 (Balint et al., 1999; Zeng et al., 1999) . These studies relied on overexpression of both HDM2 and p73. However, the mechanism by which HDM2-binding affects p73 stability under physiological conditions has not been determined. Thus, we asked whether dissociation of p73-HDM2 by Nutlin-3 affects the physiologic levels of p73 and HDM2. As expected, Nutlin-3 increased both p53 and HDM2 expression in HCT116 (p53 þ / þ ) cells (Figure 5a ), consistent with the stabilization of p53 and the feedback regulation of HDM2 by p53. We also observed an increase in HDM2 levels in Nutlin-3-treated HCT116(p53À/À) cells (Figure 5a ). To determine whether this increase in HDM2 in p53-null cells was due to p73 transcriptional activation of HDM2, we inhibited p73 expression using p73 siRNA. HDM2 induction by Nutlin-3 was diminished in cells transfected with p73 siRNA (Figure 5b ), suggesting that like p53, p73 induces HDM2. Interestingly, in addition to enhanced p73 activity, we also observed increased TAp73a protein levels in both p53 wt and mutant cells following Nutlin-3 treatment (Figures 5a and c) . The observed increase in TAp73a could be due to stabilization of p73 protein or increased p73 transcription. Cycloheximide studies demonstrated that p73 protein is stabilized in the presence of Nutlin-3. The half-life of p73 increased by 3.0-and 4.5-fold in SK-N-BE2 and HCT116(p53À/À) cells, respectively (Figures 5d and e) . We next asked whether p73 was also upregulated at the transcriptional level as a result of E2F-1 activation. We have previously shown that E2F-1, a transcription factor and HDM2-binding protein, can induce apoptosis independent of p53 by inducing the transcription of p73 (Irwin et al., 2000) . However, following Nutlin-3 treatment we did not detect increased p73mRNA levels or activation of a luciferase reporter of the p73 promoter containing E2F-1 consensus binding sites (Irwin et al., 2000; Supplementary Figure S5) . Therefore, upregulation of p73 protein by Nutlin-3 is a result of enhanced protein and not increased p73 transcription.
Discussion
Nutlins were first identified as a class of selective smallmolecule inhibitors of HDM2 (Vassilev et al., 2004) . They bind to the p53-binding pocket of HDM2 and prevent the binding of p53 to HDM2. Since its initial The HA-TAp73a-pcDNA3 and HDM2-pCDNA3.1 plasmids were either in vitro translated (IVT) separately (lanes 1, 2, 5 and 6) or cotranslated (lanes 3, 4, 7 and 9) with or without Nutlin-3 (20 mM), followed by HDM2 IP and immunoblot with HDM2 (SMP-14) and hemagglutinin (HA) antibodies.
Nutlin-3 activates p73 LMS Lau et al discovery, Nutlin-3 has been shown to be effective in a variety of cancers with wt p53, but was considered to be inactive in cells with mutant p53, which represent 50% of all cancers. p73, a p53 family protein, plays an important role in chemosensitivity of cancer cells, particularly when p53 is inactivated (Irwin, 2004) . Our data demonstrate that p53-null and p53-mutant cells are sensitive to Nutlin-3, suggesting engagement of p53-independent pathways. Since p73 binds to the hydrophobic pocket of HDM2, the same region targeted by Nutlin-3, we asked whether Nutlin-3 could inhibit binding between p73 and its negative regulator HDM2.
In this study, we show that Nutlin-3 prevents p73-HDM2 binding, resulting in increased p73 transcriptional activity and apoptosis in cells lacking functional p53. Although previous studies had identified a physical interaction between exogenous p73 and HDM2 (Balint et al., 1999; Zeng et al., 1999) , this represents the first evidence for both an endogenous p73-HDM2 interaction and disruption of the p73-HDM2 complex by Nutlin-3. Our studies demonstrate that dose-dependent inhibition of p73-HDM2 binding parallels the induction of p73 activity. Furthermore, an in vitro p73-HDM2 complex can be disrupted by Nutlin-3, providing evidence that the interaction between p73 and HDM2 is direct and therefore not mediated by other HDM2-binding proteins.
While the IC 50 is close to 1 mM for both Nutlin-3 (Laurie et al., 2006) and its active enantiomer Nutlin-3a (Vassilev et al., 2004) in p53 wt cells, the IC 50 is found to be significantly higher in p53-null and p53-mutant cells. This relative difference in Nutlin efficacy based on p53 status is consistent with previous reports (Van Maerken et al., 2006; Ambrosini et al., 2007) . Although the inhibition constant (K i ) is reported to be 0.09 mM for Nutlin-3a (Vassilev et al., 2004) and 0.7 mM for Nutlin-3 (Laurie et al., 2006) in p53 wt cells in vitro, numerous studies have reported that 10 mM of Nutlin-3 or Nutlin-3a is needed to disrupt the p53-HDM2 complex and elicit maximal downstream effects in vivo (Vassilev et al., 2004; Laurie et al., 2006; Patton et al., 2006; Tovar et al., 2006; Larusch et al., 2007) . This difference in dosing required to disrupt the p53-HDM2 complex is in keeping with our observation that while 1 mM of Nutlin-3 partially prevents the binding of p73 to HDM2, 20-30 mM is required to both maximally disrupt the p73-HDM2 complex and optimally activate p73 and induce apoptosis. Furthermore, although the three ) that occupy the HDM2 pockets are identical in p73, the N-terminal TA domain of p53 and p73 are only 30% identical (Irwin, 2004) . This difference in amino acid sequence at the HDM2-binding region may contribute to differences in the affinity of HDM2 for p53 and p73, and hence, the higher dose of Nutlin-3 required to maximally disrupt the p73-HDM2 complex. Similarly, Laurie et al. (2006) reported that much higher doses of Nutlin-3 are required to inhibit p53-HDMX binding (K i ¼ 28 mM) as compared to p53-HDM2 binding (K i ¼ 0.7 mM).
Proteins with homology to HDM2, such as HDMX, are also potential targets for Nutlin-3. The p53-binding domain of HDM2 is conserved in HDMX, which binds to and inhibits p53 (Bottger et al., 1999) . Thus, it is plausible that Nutlin-3 could also disrupt the p73-HDMX complex. Although a physical interaction between exogenous p73 and HDMX has been described (Ongkeko et al., 1999; Wang et al., 2001) , further studies will be required to determine whether p73 and HDMX form endogenous complexes in cancer cells and whether Nutlin-3 can disrupt this complex.
Previous data have demonstrated that transfected HDM2 does not target p73 for ubiquitin-mediated degradation (Balint et al., 1999; Zeng et al., 1999) . However, our data indicate that dissociation of p73-HDM2 complex and upregulation of p73 activity by Nutlin-3 is, at least in part, due to effects on p73 protein levels. This Nutlin-induced stabilization of endogenous p73 raises the possibility that HDM2-binding either directly or indirectly promotes degradation of p73 when both proteins are monitored at physiological levels. For example, in Nutlin-3-treated cells, free HDM2 not bound to p73 may affect other proteins, including E3 ligases that can modulate p73 stability. Alternatively, proteins that stabilize p73 may compete with HDM2 for binding to the N-terminus of TAp73 and thus the association of p73 with such proteins may be enhanced indirectly by Nutlin-3. The precise molecular mechanisms that regulate p73 stability in response to Nutlin-3 remain to be elucidated.
In addition to p73 protein stabilization, we explored upregulation of p73 transcription by E2F-1 as another plausible explanation for Nutlin-3-mediated p73 activation. We have previously shown that E2F-1, a transcription factor and an N-terminal HDM2-binding protein, can induce apoptosis independent of p53 by inducing p73 transcription (Irwin et al., 2000) . Interestingly, Nutlin-3 has recently been shown to inhibit E2F-1 binding to HDM2, leading to activation of E2F-1 and potentiation of chemotherapy-induced apoptosis in p53-mutant but not wt cells (Ambrosini et al., 2007) . However, in our model using Nutlin-3 alone, we did not observe increased p73 transcription or activation of an E2F-1-responsive p73 promoter. In contrast, our Nutlin-3 activates p73 LMS Lau et al data demonstrate that Nutlin-3 alone induces p73 protein stabilization as well as enhanced TAp73 transcriptional activity. Thus, the increase in E2F-1 transcriptional activity and p73 protein levels reported by Ambrosini et al. (2007) is likely due to the combination treatment with cisplatin chemotherapy and Nutlin-3 since chemotherapies including cisplatin and doxorubicin are known to activate both E2F1 and TAp73 (Irwin, 2004) .
Many other proteins interact with HDM2. Since Nutlin-3 specifically targets the N-terminal hydrophobic pocket of HDM2, it would likely only interfere with proteins that bind the N-terminus of HDM2. This specificity is supported by Kulikov et al. (2006) , who reported that the association of p53 with mutant HDM2, lacking the N-terminus, via the central acidic domain was resistant to Nutlin-3. Furthermore, Ma et al. (2006) demonstrated that Nutlin-3 was ineffective in inhibiting HDM2 ubiquitin ligase activity, which was mediated by the interaction of full-length p53 with the central domain of HDM2. In addition to p53, p73 and E2F-1, only a few proteins are known to interact with HDM2 in the same N-terminal region (residues 23-108). These proteins, including HIF1a (Larusch et al., 2007) , p63 (Calabro et al., 2002) , numb and the transcription factor TFIIE (Iwakuma and Lozano, 2003) , could potentially be modulated by Nutlin-3. Recently, Nutlin-3 was shown to prevent HDM2 binding to HIF1a, resulting in diminished HIF1a activity and attenuation of vascular endothelial growth factor (VEGF) induction (Larusch et al., 2007) . However, the interaction of numb or TFIIE with HDM2 or the effect of Nutlin-3 on these associations has not been characterized. Finally, there are limited and contradictory reports as to whether HDM2 binding inhibits TAp63 transcriptional activities (Kadakia et al., 2001; Calabro et al., 2002) . Although p63 does not appear to be involved in Nutlin-mediated effects in our cell systems, Nutlin-3 could have potential applications in epithelial cancers that express p63, such as head and neck squamous cell carcinoma.
In summary, we demonstrate that Nutlin-3 induces apoptosis in p53-mutant and p53-deficient cells via activation of p73. Thus, we provide evidence for p53-independent regulation of apoptosis mediated by HDM2-binding proteins, in keeping with recent reports where Nutlin-3 was shown to induce p21 in p53-deficient cells (VanderBorght et al., 2006) , activate E2F-1 in p53-mutant cells (Ambrosini et al., 2007) , block VEGF induction by HIF1a (Larusch et al., 2007) and inhibit viability in p53-mutant neuroblastoma cells (Van Maerken et al., 2006) . For the first time we demonstrate an endogenous interaction between p73 and HDM2 and show that disruption of this complex by Nutlin-3 enhances p73 transcriptional activity and p73 half-life, thus providing the first evidence for regulation of endogenous p73 activity by HDM2 in tumor cells. As the closely related p53 family member proteins exist as an intricate network affecting chemosensitivity (Irwin, 2004) , therapeutic modulation of p53 and/or p73 function utilizing small-molecule HDM2 inhibitors may enhance response to chemotherapy, irrespective of p53 status, through potentiation of p73-dependent apoptosis. These findings support the use of Nutlin alone, or in combination with chemotherapy, in the treatment of tumors with wt p53 or mutant p53 by activating p73-dependent apoptotic pathways.
Materials and methods
Cell culture and drug treatments Cell culture and drug treatments are discussed in Supplementary Material.
Cell viability assay
Cell proliferation was measured with MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric assays (Roche Applied Science, Laval, QC, Canada).
Immunoblotting and immunoprecipitation
Immunoblots and immunoprecipitations (IP) were carried out as previously described (Irwin et al., 2003; Watson et al., 2006) using the following antibodies: noxa, p53, HDM2, p21 waf1/cip1 , cleaved-PARP, p63 (4A4), mouse immunoglobulin G (IgG), p73, hemaglutinin (HA), vinculin, tubulin, b-actin and horseradish peroxidase-conjugated secondary antibodies. Details of antibodies are found in Supplementary Material.
In vitro translation and plasmids
In vitro translation (IVT) was carried out using TNT reticulocyte lysate (Promega, Madison, WI, USA). Reactions were preincubated with either Nutlin-3 or nuclease-free water during the final 30 min of reaction. IP were carried out in 350 ml of NETN buffer containing the same concentration of Nutlin-3 or vehicle. pcDNA3-HA-TAp73a (Irwin et al., 2000) and pCMV-HDM2 plasmids have been described (Watson et al., 2006) . pCDNA3-HDM2 plasmid was generated by BamHI excision of HDM-2 from pCMV-HDM2, followed by ligation into BamHI digested pcDNA3.1.
Reverse transcriptase-PCR and siRNA
Reverse transcriptase (RT)-PCR and siRNA details, including oligonucleotide sequences, are available in Supplementary material.
Cycloheximide assay
Cells were pretreated with Nutlin-3 for 30 min before cycloheximide (20 mg/ml) (Sigma-Aldrich, Oakville, ON, Canada) was added. Lysates were harvested at the indicated times post cycloheximide treatment. p73 levels were quantified by densitometry using the ImageJ software (http://rsb.info.nih. gov/ij).
